a2 Milk lifts estimate of China sales recovery to about 50% of pre-disruption levels
Key Facts
a2 Milk said in an update at its annual meeting on November 19 that estimated sales of Chinese-label infant formula products had recovered to about 50% of pre-supply-disruption levels, compared with about 40% in August 2026. The update points to a partial improvement in the performance of products affected by shortages, while sales remain well below their pre-disruption levels. The company expects total infant formula sales in fiscal 2027 to remain broadly in line with fiscal 2026. It said sales of Chinese- and English-label products would recover gradually during the year. This links the recovery path to product availability and a return in demand, rather than simply to an improvement in the stated sales estimate.
The company said shortages of Chinese-label infant formula products materially affected their availability in the market during the fourth quarter of fiscal 2026. The shortages prompted a significant proportion of existing users to switch to alternative brands, making the return of those consumers one of the challenges facing the recovery. In an April update, the company said supply pressures included strong demand, shipping challenges and production backlogs at Synlait, as well as longer product-release and customs-clearance processes. At the time, it expected a material impact on the availability of Chinese-label products during the fourth quarter of fiscal 2026. a2 Milk expects product shortages to continue affecting infant formula sales in fiscal 2027, even as its sales estimate improves to about half of pre-disruption levels.
The disruption also affected English-label products, albeit indirectly. a2 Milk said fourth-quarter fiscal 2026 sales of English-label infant formula products were affected by a recall of U.S.-label products announced in May 2026. The company therefore faced pressure across two product channels, with the direct cause differing between limited availability of Chinese-label products and the recall involving U.S.-label products. The company says sales of both Chinese- and English-label products will recover gradually during fiscal 2027. This puts its expectation that total infant formula sales will remain close to the previous year’s level in the context of past disruptions to product availability and user confidence.
The company’s recovery outlook is based on the launch of two new Chinese-label products and an update to a2 Platinum. It also said a resolution to Chinese import requirements currently affecting a2 Genesis was still pending. The company did not specify when those requirements would be resolved, but listed the two new products and the update among the factors supporting a gradual recovery. It expects to increase marketing spending to support a recovery in infant formula sales, particularly in the first half of fiscal 2027. Meanwhile, it expects group revenue and earnings before interest, taxes, depreciation and amortization to be heavily weighted toward the second half of the fiscal year.
a2 Milk expects fiscal 2027 revenue to grow by a mid-single-digit percentage compared with fiscal 2026, with revenue slightly lower in the first half than in the corresponding period. It estimated an underlying operating margin of about 15% for fiscal 2027, while expecting a material decline in the margin in the first half. This accompanies its expectation that results will be concentrated in the second half, leaving the year unevenly split between its two halves according to the company’s estimates. The company raised its estimate of one-off transition costs to about NZ$15 million in fiscal 2027. It does not expect additional transition costs in fiscal 2028.
The company’s outlook comes amid a slowdown in indicators of Chinese economic activity in October 2026. Data from China’s National Bureau of Statistics showed total retail sales rose 0.4% year on year, while sales of grain, oil and food products increased 0.5%. Industrial output growth slowed to 4.8% from 5.5% in September, below Reuters’ poll forecast of 5.3%, Reuters reported. Retail sales growth also slowed to 0.4% from 1.1% the previous month, compared with a forecast of 0.8%. These figures are broad indicators of the Chinese market, while the company’s own fiscal 2027 outlook is for a gradual recovery in sales of both label types and total infant formula sales to remain close to fiscal 2026 levels.